amniotic fluid
Biologicalexperimental
The amniotic fluid is the protective liquid contained by the amniotic sac of a gravid amniote. This fluid serves as a cushion for the growing fetus, but also serves to facilitate the exchange of nutrients, water, and biochemical products between mother and fetus. — Wikipedia
Clinical trial activity
21 trials · 19 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
12
Phase 3
2
Phase 4
1
Earliest trial started Mar 31, 2010 (NCT01463722)
Timeline
Indications
Studied for
- Athletic Injuries · Phase 2/Phase 3
- COVID-19 · Phase 1/Phase 2
- Graft vs Host Disease · Phase 2
- Intervertebral Disc Degeneration · Phase 2/Phase 3
- Leg Ulcer · Phase 2
- Ligaments · Phase 2/Phase 3
- Lung Diseases · Phase 2
- Multiple Sclerosis, Chronic Progressive · Phase 1/Phase 2
- Osteoarthritis · Phase 2/Phase 3
- Osteoarthritis, Knee · Phase 1/Phase 2
- Pelvic Pain · Phase 2/Phase 3
- Peripheral Nerve Injuries · Phase 2/Phase 3
- Photorefractive Keratectomy · Phase 1/Phase 2
- Pregnancy, High-Risk · Phase 4
- Pulmonary Disease, Chronic Obstructive · Phase 1/Phase 2
- Tendinopathy · Phase 2/Phase 3
- Tendon Entrapment · Phase 3
- Varicose Ulcer · Phase 2
- Wound Healing · Phase 4
- Wounds and Injuries · Phase 1/Phase 2
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAmniotic fluid ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06841068 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2026 | Wake Forest University |
| NCT06728228 | N/A | Dec 5, 2024 | Fetal Care Center, PLLC, Medical City Children's Hospital, Dallas |
| NCT06606561 | Phase 1/Phase 2 (Phase 2) | Oct 13, 2024 | Nova Vita Laboratory |
| NCT06531356 | Phase 4 | Feb 16, 2024 | Cairo University |
| NCT05643729 | Phase 1/Phase 2 (Phase 2) | Dec 18, 2022 | Organicell Regenerative Medicine, Inc, Proxima |
| NCT05228899 | Phase 1/Phase 2 (Phase 2) | Apr 14, 2022 | Organicell Regenerative Medicine, Inc, Proxima |
| NCT04886960 | Phase 1/Phase 2 (Phase 2) | Jul 8, 2021 | University of Utah |
| NCT04647240 | Phase 2 | Jul 1, 2021 | Department of Veteran Affairs, Merakris Therapeutics |
| NCT04438174 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2021 | University of Utah |
| NCT04497389 | Phase 1/Phase 2 (Phase 2) | Oct 28, 2020 | University of Utah |
| NCT04281004 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2020 | University of Utah |
| NCT04319731 | Early Phase 1 (Phase 1) | Mar 20, 2020 | University of Utah |
| NCT04465071 | N/A | Feb 24, 2020 | University of London |
| NCT04088383 | N/A | Sep 10, 2019 | Globus Medical Inc |
| NCT03298815 | Phase 2 | Jan 31, 2019 | University of Utah |
| NCT03583151 | Phase 3 | May 10, 2018 | Athens Orthopedic Clinic, J&M Shuler, Vivex Biomedical, Inc. |
| NCT03390920 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2017 | R3 Stem Cell |
| NCT03074526 | N/A | Jan 23, 2017 | MiMedx Group, Inc., University of California, San Francisco |
| NCT02768155 | N/A | Apr 30, 2016 | MiMedx Group, Inc. |
| NCT01463722 | Phase 2 | Mar 31, 2010 | Isfahan University |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (19)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Utah | Academic/Hospital | 6 | 6 | 2 | 2019 |
| Organicell Regenerative Medicine, Inc | For profit | 3 | 3 | 2 | 2022 |
| MiMedx Group, Inc. | For profit | 2 | 2 | 1 | 2016 |
| Proxima | For profit | 2 | 0 | 1 | 2022 |
| Athens Orthopedic Clinic | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2021 |
| Fetal Care Center, PLLC | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Globus Medical Inc | For profit | 1 | 1 | 1 | 2019 |
| Isfahan University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| J&M Shuler | For profit | 1 | 1 | 1 | 2018 |
| Medical City Children's Hospital, Dallas | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Merakris Therapeutics | For profit | 1 | 1 | 1 | 2021 |
| Nova Vita Laboratory | Academic/Hospital | 1 | 1 | 1 | 2024 |
| R3 Stem Cell | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Vivex Biomedical, Inc. | For profit | 1 | 0 | 1 | 2018 |
| Wake Forest University | Academic/Hospital | 1 | 1 | 1 | 2026 |
19 organizations
Page 1 / 1